255 related articles for article (PubMed ID: 9916724)
1. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.
Zeh HJ; Perry-Lalley D; Dudley ME; Rosenberg SA; Yang JC
J Immunol; 1999 Jan; 162(2):989-94. PubMed ID: 9916724
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model.
Schreurs MW; Eggert AA; de Boer AJ; Vissers JL; van Hall T; Offringa R; Figdor CG; Adema GJ
Cancer Res; 2000 Dec; 60(24):6995-7001. PubMed ID: 11156402
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
Hao S; Bai O; Yuan J; Qureshi M; Xiang J
Cell Mol Immunol; 2006 Jun; 3(3):205-11. PubMed ID: 16893501
[TBL] [Abstract][Full Text] [Related]
4. Avoidance of self-reactivity results in skewed CTL responses to rare components of synthetic immunogens.
Purcell AW; Chen W; Ede NJ; Gorman JJ; Fecondo JV; Jackson DC; Zhao Y; McCluskey J
J Immunol; 1998 Feb; 160(3):1085-90. PubMed ID: 9570520
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
6. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo.
Drexler I; Antunes E; Schmitz M; Wölfel T; Huber C; Erfle V; Rieber P; Theobald M; Sutter G
Cancer Res; 1999 Oct; 59(19):4955-63. PubMed ID: 10519409
[TBL] [Abstract][Full Text] [Related]
7. Changes to peptide structure, not concentration, contribute to expansion of the lowest avidity cytotoxic T lymphocytes.
Leggatt GR; Narayan S; Fernando GJ; Frazer IH
J Leukoc Biol; 2004 Oct; 76(4):787-95. PubMed ID: 15240746
[TBL] [Abstract][Full Text] [Related]
8. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
9. Peptide affinity and concentration affect the sensitivity of M3-restricted CTLs induced in vitro.
Byers DE; Lindahl KF
J Immunol; 1999 Sep; 163(6):3022-8. PubMed ID: 10477565
[TBL] [Abstract][Full Text] [Related]
10. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide].
Tan XH; Liu C; Wan YH
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):658-61. PubMed ID: 17274369
[TBL] [Abstract][Full Text] [Related]
11. An HLA-A2 polyepitope vaccine for melanoma immunotherapy.
Mateo L; Gardner J; Chen Q; Schmidt C; Down M; Elliott SL; Pye SJ; Firat H; Lemonnier FA; Cebon J; Suhrbier A
J Immunol; 1999 Oct; 163(7):4058-63. PubMed ID: 10491010
[TBL] [Abstract][Full Text] [Related]
12. Identification of shared tumor-associated antigen peptides between two spontaneous lung carcinomas.
Mandelboim O; Bar-Haim E; Vadai E; Fridkin M; Eisenbach L
J Immunol; 1997 Dec; 159(12):6030-6. PubMed ID: 9550401
[TBL] [Abstract][Full Text] [Related]
13. Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice.
Men Y; Miconnet I; Valmori D; Rimoldi D; Cerottini JC; Romero P
J Immunol; 1999 Mar; 162(6):3566-73. PubMed ID: 10092815
[TBL] [Abstract][Full Text] [Related]
14. Characterization of mouse MAGE-derived H-2Kb-restricted CTL epitopes.
Eggert AO; Andersen MH; Voigt H; Schrama D; Kämpgen E; Straten PT; Becker JC
Eur J Immunol; 2004 Nov; 34(11):3285-90. PubMed ID: 15384049
[TBL] [Abstract][Full Text] [Related]
15. High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells.
Gervois N; Labarriere N; Le Guiner S; Pandolfino MC; Fonteneau JF; Guilloux Y; Diez E; Dreno B; Jotereau F
Clin Cancer Res; 2000 Apr; 6(4):1459-67. PubMed ID: 10778978
[TBL] [Abstract][Full Text] [Related]
16. DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8+ T cells.
Pudney VA; Metheringham RL; Gunn B; Spendlove I; Ramage JM; Durrant LG
Eur J Immunol; 2010 Mar; 40(3):899-910. PubMed ID: 20039301
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
Song S; Wang F; He X; He Y; Li D; Sun S
Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
[TBL] [Abstract][Full Text] [Related]
18. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
19. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides.
Nair S; Wearsch PA; Mitchell DA; Wassenberg JJ; Gilboa E; Nicchitta CV
J Immunol; 1999 Jun; 162(11):6426-32. PubMed ID: 10352256
[TBL] [Abstract][Full Text] [Related]
20. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
Yang S; Linette GP; Longerich S; Haluska FG
J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
